Table 2.
Studies Demonstrating E484K Reduced Neutralization of Convalescent Sera
| Author | Plasma Collected Period | Country | Neutralization Method | Mutation/Variant Evaluated | Result (Decreased Neutralization Relative to Wild-Type Virus) |
|---|---|---|---|---|---|
| Jangra et al6 | No data | USA | Recombinant SARS-CoV-2s | E484K | Decrease neutralization 2.4-fold to 4.2-fold |
| Greaney et al7 | February–July 2020 | USA | Lentiviral particles pseudotyped | E484K | Decrease neutralization by >100-fold |
| Liu et al10 | Before May 2020 | USA | VSV particles pseudotyped | E484 (including E484A, E484D, E484G and E484K) | Decrease neutralization |
| Gaebler et al16 | August 31– October 16, 2020 | USA | HIV-1 particles pseudotyped | K417N/E484K/N501Y | Decrease neutralization by 0.5- to 29-fold |
| Wang et al15 | |||||
| Chen et al17 | No data | USA | Vero-hACE2-TMPRSS2 cells | Alpha variant | No difference |
| E484K/N501Y | Decrease neutralization by 5-fold | ||||
| Wibmer et al18 | May–September 2020 | South Africa | Lentiviral particles pseudotyped | K417N/E484K/N501Y | Loss of neutralization in 27% of the samples |
| Collier et al19 | No data | UK | Lentiviral particles pseudotyped | Alpha variant combined with E484K | Decrease neutralization by 11.4-fold |
| Shen et al28 | No data | USA | Lentiviral particles pseudotyped | Beta variant | Decrease neutralization by 13.1-fold (relative to D614G) |